|
DOCTORATE in GENETICS, ONCOLOGY and CLINICAL MEDICINE (GenOMeC)
DOTTORATO DI
RICERCA IN GENETICA ONCOLOGIA E MEDICINA CLINICA
UNIVERSITA' DEGLI STUDI DI SIENA
Home Page |
| Publications
during the PhD program |
| |
| Defina Marzia |
| |
|
1)
Cutaneous myeloma and bortezomib.
Gozzetti A, Defina M, Bocchia M.
Ann Hematol.
2009 Oct;88(10):1045.
2)
Lenalidomide on alternative days is effective
in myelodysplastic syndrome with 5q- deletion.
Defina M, Rondoni M, Gozzetti A, Aprile L,
Chitarrelli I, Fabbri A, Lauria F, Bocchia M.
Br J
Haematol. 2010 Feb;148(3):483-4.
3)
Translocation(X;2)(q26;q11.2) in a patient
with acute myeloid leukemia M2 evolved from essential
thrombocytemia.
Gozzetti A, Crupi R, Rondoni M,
Daviddi B, Defina M, Bocchia M, Pietrini A, Raspadori D,
Lauria F.
Cancer Genet Cytogenet. 2010 Feb;197(1):84-5
4)
Hyperlipidemic myeloma.
Gozzetti A, Defina M, Bocchia M,
Lauria F.
Ann
Hematol. 2010 Sep;89(9):939-40.
5)
Dexamethasone plus rituximab
yields higher sustained response rates than
dexamethasone monotherapy in adults with primary
immune thrombocytopenia.
Zaja F, Baccarani M, Mazza
P, Bocchia M, Gugliotta L, Zaccaria A, Vianelli
N, Defina M, Tieghi A, Amadori S, Campagna S,
Ferrara F, Angelucci E, Usala E, Cantoni S,
Visani G, Fornaro A, Rizzi R, De Stefano V,
Casulli F, Battista ML, Isola M, Soldano F,
Gamba E, Fanin R.
Blood.
2010 Apr 8;115(14):2755-62.
6)
Very late relapse in a patient with chronic
myeloid leukemia in sustained complete
cytogenetic response under imatinib.
Defina M, Gozzetti A, Rondoni M, Aprile L,
Ippoliti M, Chitarrelli I, Lauria F, Bocchia M.
Leukemia Research. 2010 Aug;34(8):e215-6
7)
Safety and efficacy of
bortezomib, melphalan and low doses
dexamethasone (VM-dex) in newly diagnosed
patients with multiple myeloma.
Gozzetti A, Defina M,
Bocchia M, Fabbri A, Marchini E, Chitarrelli
I, Lauria F.
Leuk Res. 2010 Nov;34(11):e288-9.
8)
Low-dose rituximab
in adult patients with primary immune
thrombocytopenia.
Zaja F,
Vianelli N, Volpetti S, Battista ML,
Defina M, Palmieri S, Bocchia M,
Medeot M, De Luca S, Ferrara F,
Isola M, Baccarani M, Fanin R.
Eur J Haematol. 2010 Oct;85(4):329-34.
9)
Reduction of
imatinib dose and persistence of
complete molecular response after
p210 multipeptide vaccine in chronic
myeloid leukaemia treated with dose
escalation for acquired resistance.
Breccia M,
Bocchia M, Cannella L, Defina M,
Ippoliti M, Loglisci G,
Santopietro M, Lauria F, Alimena
G.
Br J Haematol. 2010 Jul;150(2):240-2.
10)
Hyperlipidemia in a myeloma
patient after bortezomib
treatment.
Gozzetti A, Fabbri A,
Defina M, Chitarrelli I,
Bocchia M.
Leuk Res. 2010
Sep;34(9):e250.
11)
Weekly bortezomib,
pegylated liposomal
doxorubicin, and
dexamethasone is a
safe and effective
therapy for elderly
patients with
relapsed/refractory
multiple myeloma.
Gozzetti A,
Fabbri A, Oliva
S, Marchini E,
Bocchia M,
Defina M, Lauria
F.
Clin Lymphoma
Myeloma Leuk.
2010 Feb;10(1):68-72.
12)
A der(1)t(1;21)(p36.3;q22)
in a patient
with acute
myelogenous
leukemia M2.
Gozzetti A,
Crupi R,
Rondoni M,
Defina M,
Bocchia M,
Pietrini A,
Raspadori D,
Lauria F.
Acta
Haematol.
2010;124(1):44-5.
Epub 2010
Jul 3.
13)
Complete
molecular
response in
CML after
p210
BCR-ABL1-derived
peptide
vaccination.
Bocchia
M,
Defina
M,
Aprile
L,
Ippoliti
M, Crupi
R,
Rondoni
M,
Gozzetti
A,
Lauria
F.
Nat Rev
Clin
Oncol.
2010 Oct;7(10):600-3.
14)
Lenalidomide
efficacy
in
bortezomib-resistant
myeloma.
Gozzetti
A,
Crupi
R,
Defina
M,
Bocchia
M.
Nat
Rev
Clin
Oncol.
2010
Sep;7(9).
15)Unusual
localizations
of
plasmacytoma.
Gozzetti A, Coviello G, Fabbri A, Della Corte R, Bocchia M, Defina M, Lauria F.
Leuk Res. 2011 Jul;35(7):e104-5.
16) A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): a case report.
Gozzetti A, Cerase A, Crupi R, Raspadori D, Defina M, Bocchia M, Lauria F.
Leuk Res. 2011 Nov;35(11):e206-8.
17) Extramedullary multifocal plasmacytoma relapse in multiple myeloma.
Gozzetti A, Marchini E, Banchi B, Papini G, Defina M, Bocchia M, Lauria F.
Leuk Res. 2012 Jan;36(1):e34-6.
18) Plasmacytoma of the skull.
Gozzetti A, Cerase A, Defina M, Bocchia M.
Eur J Haematol. 2012 Apr;88(4):369.
19) Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.
Gozzetti A, Musto P, Defina M, D'Auria F, Papini G, Steduto T, D'Arena G, Bocchia M.
Br J Haematol. 2012 Feb 1.
20) Evaluation of residual CD34+Ph+ progenitor cells in chronic myeloid leukemia patients in complete cytogenetic response during first line nilotinib therapy. Marzia Defina, Micaela Ippoliti, Alessandro Gozzetti, Elisabetta Abruzzese, Fausto Castagnetti, Rosaria Crupi, Mario Tiribelli, Massimo Breccia, Marzia Salvucci, Lara Aprile, Claudia Baratè, Antonella Gozzini, Gianantonio Rosti, Francesco Lauria and Monica Bocchia. Cancer. 2012. In press
21) Extramedullary myeloma relapses.
Gozzetti A, Papini G, Defina M, Bocchia M.
Ann Hematol. 2012 Feb 25.
|
|
|
|
|
| |
| |
|
|
|
|
|
|
|
|
|